Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Berberine is a quaternary ammonium salt from the protoberberine group of benzylisoquinoline alkaloids. It occurs naturally in several plants including Coptis chinensis (goldthread), Hydrastis canadensis (goldenseal), and Berberis species. Structurally it features a tetracyclic skeleton with a dihydroisoquinoline and isoquinoline ring system. In clinical use—primarily in China—it is an over-the-counter drug for diarrhea due to bacterial infections such as *E. coli* and *Shigella*. Pharmacologically it exhibits antimicrobial activity (notably antibacterial and antifungal), positive inotropic effects on the heart muscle, negative chronotropic effects (slowing heart rate), antiarrhythmic properties, vasodilation activity as well as hypoglycemic and lipid-lowering effects observed in preclinical studies. Its mechanism includes inhibition of CYP3A4 enzyme activity affecting drug metabolism[1][2][3][6]. In Western countries it is widely marketed as a dietary supplement but not approved by regulatory agencies for any specific medical indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on berberine.